NEW YORK, Nov. 30—Abbott Laboratories concluded its acquisition of Vysis as scheduled at midnight on November 29.

The pharmaceutical company commenced a cash tender offer on Oct. 31 to purchase all outstanding shares of the genomics-based disease management company. 

As a final step, remaining Vysis shareholders will receive the same $30.50 per share cash price as paid in the tender offer.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.